Female Breast Cancer Clinical Trial
Official title:
Evaluation of Adjuvant Endocrine Therapy for Operable ER-beta Positive, ER-alpha/PR Negative, Her-2 Negative Breast Cancer Patients
The study is a prospective multi-center randomized control clinical trial which is sponsored by the researchers. The purpose of this study is to determine the effectiveness of adjuvant endocrine therapy for operable ER-beta positive, ER-alpha/PR negative, Her-2 negative breast cancer(triple negative breast cancer, TNBC) patients. The ER-beta positive TNBC patients who had undergone modified radical mastectomy or breast-conserving surgery were randomly (1:1) enrolled to receive toremifene (60 mg per day for premenopausal and perimenopausal patients) /anastrozole(1mg per day for postmenopausal patients) or observation within 4 weeks after adjuvant chemotherapy and/or radiation therapy if necessary.The follow-up time will be at least five years. The disease free survival(DFS) and overall survival(OS) between endocrine group and observation group will be compared to evaluate the effectiveness.
n/a
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT02480933 -
Silent Breast Cancer A Study of the Disease Prevalence Held by Imaging Guided Biopsies in Autopsy Specimens
|
N/A | |
| Not yet recruiting |
NCT04863833 -
Tomosymthesis for Breast Mass Lesion Characterization
|
||
| Completed |
NCT05000502 -
Exercise, Gut Microbiome, and Breast Cancer: Increasing Reach to Underserved Populations
|
N/A | |
| Withdrawn |
NCT06145399 -
A Study of 1 8F-FDHT PET/MRIScans in Women With Breast Cancer
|
Early Phase 1 | |
| Suspended |
NCT01320488 -
Breast Cancer in Young Women: Is it Different?
|
N/A | |
| Active, not recruiting |
NCT01741883 -
Side Effect Prevention Training (SEPT) for Nocebo Effects in Breast Cancer Patients
|
N/A | |
| Recruiting |
NCT06144164 -
A Study of a Comprehensive Prevention Program to Reduce Lymphedema After Axillary Lymph Node Dissection in People With Breast Cancer
|
Phase 3 | |
| Recruiting |
NCT06331793 -
Pulsed Electromagnetic Fields for Analgesia Post Mastectomy
|
N/A | |
| Recruiting |
NCT05439499 -
This is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of FCN-437c Versus Placebo in Combination With Letrozole or Anastrozole ± Goserelin in Women With HR+ and HER2- Advanced Breast Cancer.
|
Phase 3 | |
| Terminated |
NCT03836872 -
Acupuncture for Joint Symptoms in Patients With Breast Cancer
|
N/A | |
| Recruiting |
NCT06332976 -
PrefeRences And ChemoTherapy In Breast Cancer patiEnts
|
||
| Completed |
NCT01671319 -
Dose Dense TC + Pegfilgrastim Support for Breast Cancer
|
Phase 2 | |
| Not yet recruiting |
NCT06092892 -
IIT2023-09-Chung-UpfrontTAD: Upfront TAD/SNB in Patients With Breast Cancer With Nodal Metastases
|
Phase 2 | |
| Recruiting |
NCT05586256 -
Ultra-hypofractionated Radiotherapy in Breast Cancer Patients
|
||
| Not yet recruiting |
NCT03153631 -
Female Sexual Dysfunction in Breast Cancer Patients
|
N/A | |
| Active, not recruiting |
NCT03059875 -
Place of Comprehensive Geriatric Assessment in Patients ≥ 75 Years Care, With Breast Cancer, After Screening With FOG (Oncology Geriatric Filter)
|
N/A | |
| Active, not recruiting |
NCT02088710 -
Expectations and Side Effects of Endocrine Therapy in Women With Breast Cancer
|
N/A | |
| Terminated |
NCT01083641 -
Estrogen for Triple Negative Breast Cancer
|
Phase 2 | |
| Recruiting |
NCT05374161 -
An Intervention for Female Breast CANcer: Acceptance and Commitment Therapy (I-CAN-ACT) for Depression and Physical Pain
|
N/A | |
| Recruiting |
NCT05438810 -
This is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of FCN-437c in Combination With Fluvestrant ± Goseraline Versus Placebo Combined With Fulvestrant ± Goserelin in Women With HR+ and HER2- Advanced Breast Cancer.
|
Phase 3 |